Cargando…

A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options

BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Moutafi, Myrto, Ziogas, Dimitrios C., Michopoulos, Spyros, Bagratuni, Tina, Vasileiou, Vassiliki, Verga, Laura, Merlini, Giampaolo, Palladini, Giovanni, Matsouka, Charis, Dimopoulos, Meletios A., Kastritis, Efstathios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341640/
https://www.ncbi.nlm.nih.gov/pubmed/30665372
http://dx.doi.org/10.1186/s12881-019-0755-5
_version_ 1783388982367748096
author Moutafi, Myrto
Ziogas, Dimitrios C.
Michopoulos, Spyros
Bagratuni, Tina
Vasileiou, Vassiliki
Verga, Laura
Merlini, Giampaolo
Palladini, Giovanni
Matsouka, Charis
Dimopoulos, Meletios A.
Kastritis, Efstathios
author_facet Moutafi, Myrto
Ziogas, Dimitrios C.
Michopoulos, Spyros
Bagratuni, Tina
Vasileiou, Vassiliki
Verga, Laura
Merlini, Giampaolo
Palladini, Giovanni
Matsouka, Charis
Dimopoulos, Meletios A.
Kastritis, Efstathios
author_sort Moutafi, Myrto
collection PubMed
description BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CASE PRESENTATION: Among hereditary amyloidosis subtypes, we describe here a specific case of Apolipoprotein AI amyloidosis (AApoAI), where the diagnosis began from an almost asymptomatic hepatomegaly followed by the development of primary hypogonadism. Baseline laboratory tests showed increased liver enzymes, while imaging tests revealed a suspected infiltrative liver disease. Patient underwent into liver biopsy and histological examination detected the presence of periodic acid-Schiff (−) and Congo-red (+) amorphous eosinophilic material within normal liver tissue. In the typing of amyloid by immunoelectron microscopy, the liver appeared heavily infiltrated by anti-apoAI (+) amyloid fibrils. Gene sequencing and mutational analysis revealed a single-base mutation at position c.251 T > C resulting in an amino acid substitution from leucine to proline in the mature ApoAI protein. This amino acid change led to lower cleavage and ApoAI deposition into the involved organs. Few years later, our patient remaining without treatment, came with symptoms consistent with primary hypogonadism but testicular involvement with ApoAI deposits could not be proven since the patient refused testicular biopsy. Based on this case, we recap the diagnostic challenges, the clinical manifestations, and the potential treatment options for this indolent hereditary amyloidosis subtype. CONCLUSIONS: This case-report enlarges the clinical picture of ApoAI-driven disease and its complex genetic background and in parallel suggests for a more systematic approach in any case with strong suspicion of hereditary amyloidosis.
format Online
Article
Text
id pubmed-6341640
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63416402019-01-24 A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options Moutafi, Myrto Ziogas, Dimitrios C. Michopoulos, Spyros Bagratuni, Tina Vasileiou, Vassiliki Verga, Laura Merlini, Giampaolo Palladini, Giovanni Matsouka, Charis Dimopoulos, Meletios A. Kastritis, Efstathios BMC Med Genet Case Report BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CASE PRESENTATION: Among hereditary amyloidosis subtypes, we describe here a specific case of Apolipoprotein AI amyloidosis (AApoAI), where the diagnosis began from an almost asymptomatic hepatomegaly followed by the development of primary hypogonadism. Baseline laboratory tests showed increased liver enzymes, while imaging tests revealed a suspected infiltrative liver disease. Patient underwent into liver biopsy and histological examination detected the presence of periodic acid-Schiff (−) and Congo-red (+) amorphous eosinophilic material within normal liver tissue. In the typing of amyloid by immunoelectron microscopy, the liver appeared heavily infiltrated by anti-apoAI (+) amyloid fibrils. Gene sequencing and mutational analysis revealed a single-base mutation at position c.251 T > C resulting in an amino acid substitution from leucine to proline in the mature ApoAI protein. This amino acid change led to lower cleavage and ApoAI deposition into the involved organs. Few years later, our patient remaining without treatment, came with symptoms consistent with primary hypogonadism but testicular involvement with ApoAI deposits could not be proven since the patient refused testicular biopsy. Based on this case, we recap the diagnostic challenges, the clinical manifestations, and the potential treatment options for this indolent hereditary amyloidosis subtype. CONCLUSIONS: This case-report enlarges the clinical picture of ApoAI-driven disease and its complex genetic background and in parallel suggests for a more systematic approach in any case with strong suspicion of hereditary amyloidosis. BioMed Central 2019-01-21 /pmc/articles/PMC6341640/ /pubmed/30665372 http://dx.doi.org/10.1186/s12881-019-0755-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Moutafi, Myrto
Ziogas, Dimitrios C.
Michopoulos, Spyros
Bagratuni, Tina
Vasileiou, Vassiliki
Verga, Laura
Merlini, Giampaolo
Palladini, Giovanni
Matsouka, Charis
Dimopoulos, Meletios A.
Kastritis, Efstathios
A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
title A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
title_full A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
title_fullStr A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
title_full_unstemmed A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
title_short A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
title_sort new genetic variant of hereditary apolipoprotein a-i amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341640/
https://www.ncbi.nlm.nih.gov/pubmed/30665372
http://dx.doi.org/10.1186/s12881-019-0755-5
work_keys_str_mv AT moutafimyrto anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT ziogasdimitriosc anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT michopoulosspyros anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT bagratunitina anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT vasileiouvassiliki anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT vergalaura anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT merlinigiampaolo anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT palladinigiovanni anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT matsoukacharis anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT dimopoulosmeletiosa anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT kastritisefstathios anewgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT moutafimyrto newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT ziogasdimitriosc newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT michopoulosspyros newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT bagratunitina newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT vasileiouvassiliki newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT vergalaura newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT merlinigiampaolo newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT palladinigiovanni newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT matsoukacharis newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT dimopoulosmeletiosa newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions
AT kastritisefstathios newgeneticvariantofhereditaryapolipoproteinaiamyloidosisacasereportfollowedbydiscussionofdiagnosticchallengesandtherapeuticoptions